148 related articles for article (PubMed ID: 20526381)
1. Does Finasteride Affect the Severity of Prostate Cancer? A Causal Sensitivity Analysis.
Shepherd BE; Redman MW; Ankerst DP
J Am Stat Assoc; 2008 Dec; 103(484):1392-1404. PubMed ID: 20526381
[TBL] [Abstract][Full Text] [Related]
2. PCPT: Evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer.
Kaplan SA; Roehrborn CG; Meehan AG; Liu KS; Carides AD; Binkowitz BS; Heyden NL; Vaughan ED
Urology; 2009 May; 73(5):935-9. PubMed ID: 19328538
[TBL] [Abstract][Full Text] [Related]
3. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial.
Cohen YC; Liu KS; Heyden NL; Carides AD; Anderson KM; Daifotis AG; Gann PH
J Natl Cancer Inst; 2007 Sep; 99(18):1366-74. PubMed ID: 17848668
[TBL] [Abstract][Full Text] [Related]
4. New answers from the Prostate Cancer Prevention Trial on the chemoprevention of prostate cancer.
Ankerst DP; Thompson IM
Arch Ital Urol Androl; 2006 Dec; 78(4):154-6. PubMed ID: 17269622
[TBL] [Abstract][Full Text] [Related]
5. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach.
Redman MW; Tangen CM; Goodman PJ; Lucia MS; Coltman CA; Thompson IM
Cancer Prev Res (Phila); 2008 Aug; 1(3):174-81. PubMed ID: 19138953
[TBL] [Abstract][Full Text] [Related]
6. Estimated impact of the Prostate Cancer Prevention Trial on population mortality.
Unger JM; Thompson IM; LeBlanc M; Crowley JJ; Goodman PJ; Ford LG; Coltman CA
Cancer; 2005 Apr; 103(7):1375-80. PubMed ID: 15739207
[TBL] [Abstract][Full Text] [Related]
7. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer.
Thompson IM; Chi C; Ankerst DP; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
J Natl Cancer Inst; 2006 Aug; 98(16):1128-33. PubMed ID: 16912265
[TBL] [Abstract][Full Text] [Related]
8. Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial.
Winchester DA; Till C; Goodman PJ; Tangen CM; Santella RM; Johnson-Pais TL; Leach RJ; Xu J; Zheng SL; Thompson IM; Lucia MS; Lippman SM; Parnes HL; Isaacs WB; De Marzo AM; Drake CG; Platz EA
Prostate; 2017 Jun; 77(8):908-919. PubMed ID: 28317149
[TBL] [Abstract][Full Text] [Related]
9. Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes.
Lotan Y; Cadeddu JA; Lee JJ; Roehrborn CG; Lippman SM
J Clin Oncol; 2005 Mar; 23(9):1911-20. PubMed ID: 15774783
[TBL] [Abstract][Full Text] [Related]
10. Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention.
Lucia MS; Darke AK; Goodman PJ; La Rosa FG; Parnes HL; Ford LG; Coltman CA; Thompson IM
Cancer Prev Res (Phila); 2008 Aug; 1(3):167-73. PubMed ID: 19138952
[TBL] [Abstract][Full Text] [Related]
11. Finasteride as a chemopreventive agent in prostate cancer: impact of the PCPT on urologic practice.
Goetzl MA; Holzbeierlein JM
Nat Clin Pract Urol; 2006 Aug; 3(8):422-9. PubMed ID: 16902518
[TBL] [Abstract][Full Text] [Related]
12. [The pathologist's perspective on the PCPT trial].
Molinié V; Allory Y
Prog Urol; 2008 Apr; 18 Suppl 3():S47-52. PubMed ID: 18455084
[TBL] [Abstract][Full Text] [Related]
13. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial.
Etzioni RD; Howlader N; Shaw PA; Ankerst DP; Penson DF; Goodman PJ; Thompson IM
J Urol; 2005 Sep; 174(3):877-81. PubMed ID: 16093979
[TBL] [Abstract][Full Text] [Related]
14. Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection.
Thompson IM; Tangen CM; Goodman PJ; Lucia MS; Parnes HL; Lippman SM; Coltman CA
J Urol; 2007 May; 177(5):1749-52. PubMed ID: 17437804
[TBL] [Abstract][Full Text] [Related]
15. Sensitivity and specificity of prostate-specific antigen for prostate cancer detection with high rates of biopsy verification.
Ankerst DP; Thompson IM
Arch Ital Urol Androl; 2006 Dec; 78(4):125-9. PubMed ID: 17269614
[TBL] [Abstract][Full Text] [Related]
16. Prevention of prostate cancer with finasteride: US/European perspective.
Thompson IM; Klein EA; Lippman SM; Coltman CA; Djavan B
Eur Urol; 2003 Dec; 44(6):650-5. PubMed ID: 14644115
[TBL] [Abstract][Full Text] [Related]
17. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.
Thompson IM; Pauler Ankerst D; Chi C; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
J Clin Oncol; 2007 Jul; 25(21):3076-81. PubMed ID: 17634486
[TBL] [Abstract][Full Text] [Related]
18. Finasteride modifies the relation between serum C-peptide and prostate cancer risk: results from the Prostate Cancer Prevention Trial.
Neuhouser ML; Till C; Kristal A; Goodman P; Hoque A; Platz EA; Hsing AW; Albanes D; Parnes HL; Pollak M
Cancer Prev Res (Phila); 2010 Mar; 3(3):279-89. PubMed ID: 20179296
[TBL] [Abstract][Full Text] [Related]
19. Assessing benefit and risk in the prevention of prostate cancer: the prostate cancer prevention trial revisited.
Klein EA; Tangen CM; Goodman PJ; Lippman SM; Thompson IM
J Clin Oncol; 2005 Oct; 23(30):7460-6. PubMed ID: 16157937
[TBL] [Abstract][Full Text] [Related]
20. Five-alpha-reductase Inhibitors for prostate cancer prevention.
Wilt TJ; MacDonald R; Hagerty K; Schellhammer P; Kramer BS
Cochrane Database Syst Rev; 2008 Apr; (2):CD007091. PubMed ID: 18425978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
